Starpharma signs license for VivaGel Condom in Iran
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
In the deck
Story so far
Earlier from Starpharma
- Additional Priostar Glyphosate Patent Allowed in US
- Enrolment complete for Phase 3 VivaGel BV-R program
- VivaGel condom receives regulatory approval in Canada
- New DEP drug delivery program initiated with AstraZeneca
- Starpharma signs license for a VivaGel condom in China
Later from Starpharma
- Starpharma receives $3.5M R&D tax incentive refund
- VivaGel BV granted QIDP and Fast Track designation by US FDA
- Shareholder Update January 2017
- VivaGel BV phase 3 trials for prevention of BV completed
- Ansell launches VivaGel condom in Canada
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma